Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Veeco Instruments Inc. in its acquisition of Epiluvac AB
Mandate

Vinge advises Veeco Instruments Inc. in its acquisition of Epiluvac AB

February 01, 2023 M&A IT, Telecommunications and Outsourcing Data protection and processing of personal data Intellectual Property Corporate Tax Employment and Benefits

Vinge has advised Veeco Instruments Inc. ("Veeco"), a US company listed on NASDAQ, in its acquisition of Epiluvac AB, a privately held manufacturer of chemical vapor deposition epitaxy systems that enable advanced silicon carbide (“SiC”) applications in the electric vehicle market. Epiluvac, based in Lund, Sweden, was founded in 2013 by a highly experienced team in SiC.

Epiluvac’s technology platform combined with Veeco’s global go-to-market capabilities is expected to create a significant long-term growth driver for Veeco. Epiluvac is an early-stage revenue company with 11 employees. The purchase price for the transaction, all payable in cash, is $30 million paid at the time of closing with a potential additional $35 million in performance based earn-outs.

Vinge's team consisted of, among others, Jonas Bergström, Carl Sander, Stina Bengtsson and Robin Sultani (M&A), Sofia Bergenstråhle and Arvid Axelryd (IP), Anna Ståhlklo and Jonna Skog (Employment), Victor Ericsson and Emelie Svanberg (Tax), Nicklas Thorgerzon (IT & GDPR) and Jasmina Skandrani (Project Assistant).

 

Related

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025

Vinge advises Advania in connection with the acquisition of atNorth HPC AB

Vinge has advised Advania, one of the leading IT companies in the Nordic region, in connection with the acquisition of atNorth HPC AB. The acquisition strengthens Advania's presence within high-performance computing (HPC).
October 03, 2025